October 12 2011 Pulmonary Fibrosis Foundation to Fund Further Therapeutic Evaluation Studies for Compugen-Discovered Drug Candidate

Potential use of CGEN-25009 for treatment of idiopathic pulmonary fibrosis previously demonstrated in animal disease model

TEL AVIV, Israel & CHICAGO, Oct 12, 2011 (BUSINESS WIRE) — –Studies to
be undertaken at the University of Pittsburgh School of Medicine and the Dorothy
P. and Richard P. Simmons Center for Interstitial Lung Disease

Compugen Ltd. and the Pulmonary Fibrosis Foundation announced today that the Pulmonary Fibrosis Foundation will provide a grant to scientists at the University of Pittsburgh Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease to
independently evaluate the therapeutic potential of CGEN-25009 for the treatment
of idiopathic pulmonary fibrosis (IPF), a devastating disease with no current
effective treatment and which is estimated to affect more than five million
people worldwide.

Read the entire article at:

http://www.marketwatch.com/story/pulmonary-fibrosis-foundation-to-fund-further-therapeutic-evaluation-studies-for-compugen-discovered-drug-candidate-2011-10-12

or go to www.ipftoday.com for more news.

 

This entry was posted in IPF, Medical, Pulmonary Fibrosis and tagged , , , , . Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>